OKYO Pharma Management

Management criteria checks 3/4

OKYO Pharma's CEO is Gary Jacob, appointed in Jan 2021, has a tenure of 3.83 years. total yearly compensation is $1.11M, comprised of 35.2% salary and 64.8% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $48.18K. The average tenure of the management team and the board of directors is 3.8 years and 3.4 years respectively.

Key information

Gary Jacob

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage	35.2%
CEO tenure	3.8yrs
CEO ownership	0.1%
Management average tenure	3.8yrs
Board average tenure	3.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gary Jacob's remuneration changed compared to OKYO Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	US$1m	US$392k	-US$17m
Mar 31 2023	US$1m	US$433k	-US$13m
Dec 31 2022	n/a	n/a	-US$11m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$6m
Mar 31 2022	US$2m	US$350k	-US$5m
Dec 31 2021	n/a	n/a	-US$5m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$4m
Mar 31 2021	US$872k	US$85k	-US$3m

Compensation vs Market: Gary's total compensation ($USD1.11M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.

CEO

Gary Jacob (77 yo)

3.8yrs

Tenure

US$1,114,000

Compensation

Dr. Gary S. Jacob, PhD, served as an Independent Director at Virpax Pharmaceuticals, Inc. since April 2020 until July 25, 2022. He had been an Independent Director of Cardiff Oncology, Inc. since February...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gary Jacob	CEO & Executive Director	3.8yrs	US$1.11m	0.14% $ 48.2k
Michael Beck	Founder	no data	no data	no data
Keeren Shah	Chief Financial Officer	4.3yrs	no data	no data
Rajkumar Patil	Chief Scientific Officer	3.7yrs	no data	no data

3.8yrs

Average Tenure

66yo

Average Age

Experienced Management: OKYO's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gary Jacob	CEO & Executive Director	3.8yrs	US$1.11m	0.14% $ 48.2k
Bernard Denoyer	Independent Non-Executive Director	2.9yrs	US$51.00k	0% $ 0
Gabriele Marco Cerrone	Non-Executive Chairman	3.8yrs	US$1.31m	29.12% $ 10.3m
John Brancaccio	Independent Non-Executive Director	4.4yrs	US$86.00k	0.025% $ 9.0k
Jay Pepose	Member of Scientific Advisory Board	1.8yrs	no data	no data
Willy Simon	Senior Independent Non-Executive Director	9yrs	US$50.00k	0.026% $ 9.4k
Napoleone Ferrara	Member of Scientific Advisory Board	4.3yrs	no data	no data
Pedram Hamrah	Member of Scientific Advisory Board	no data	no data	no data
Victor Perez	Member of Scientific Advisory Board	less than a year	no data	no data
Anat Galor	Member of Scientific Advisory Board	less than a year	no data	no data
Mark Milner	Member of Scientific Advisory Board	less than a year	no data	no data

3.4yrs

Average Tenure

73yo

Average Age

Experienced Board: OKYO's board of directors are considered experienced (3.4 years average tenure).

OKYO Pharma Management

Management criteria checks 3/4

Key information

Recent management updates

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

Recent updates

OKYO Pharma Limited Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age